secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028518
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Tech Q2 net loss widens to $1.7M; revenue $20k; cash $8.3M
----------------------------------------------------------------------

- Net loss of $1.7M ($0.20/sh) vs $88k ($0.03/sh) in Q2 2022; SG&A up to $1.4M from $409k.
- Revenue of $20k, up from $1k YoY, including $10k from DOD sales of CyPath Lung.
- Cash and equivalents $8.3M at June 30, 2023, down from $11.4M at Dec 31, 2022.
- AMA issued CPT code for CyPath Lung effective Oct 1, 2023; DOD purchased tests.
- Michael Dougherty appointed CFO; previously CFO of Amazon's Alexa commercial domains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223028518/0001493152-23-028518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223028518/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer